51 results
PRE 14A
STRO
Sutro Biopharma Inc
14 Apr 23
Preliminary proxy
4:05pm
and retain qualified and talented executives, incentivize them to achieve our business objectives, and reward them for superior short- and long-term performance … practices and align executive compensation with our performance, with an emphasis on long-term equity compensation in the form of stock options
8-K
EX-99.1
STRO
Sutro Biopharma Inc
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
-002 should allow for long-term dosing and dose intensity. Although a maximum tolerated dose was not reached, we have identified dose levels of 4.3
8-K
EX-99.1
ohdkgslfuxoh2v0b2q
15 Nov 18
Sutro Biopharma Reports Third Quarter 2018 Financial Results
12:00am
424B5
j0gcr
11 Oct 19
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.2
yvfq3
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
424B5
mftsfb1 n1
9 Feb 24
Prospectus supplement for primary offering
4:25pm
POSASR
0q0dmu
28 Feb 22
Automatic shelf registration (post-effective amendment)
4:16pm
POS AM
uuyjqj0woshbdcwng8ia
28 Feb 22
Prospectus update (post-effective amendment)
5:46pm
S-3ASR
y55bip14ktm
2 Apr 21
Automatic shelf registration
4:59pm
S-3
m843j eatlfgfhix
4 Oct 19
Shelf registration
4:06pm
DRS
0ono3qf9fct4 f4272vx
1 Jun 18
Draft registration statement
12:00am
DRS/A
d85kgzd
10 Jul 18
Draft registration statement (amended)
12:00am
S-3ASR
EX-1.2
ulwbymcogcevj51xf7
2 Apr 21
Automatic shelf registration
4:59pm